The involvement of the retina in CNS disease is increasingly recognized in the area of neurodegeneration, as there is accumulating evidence showing that similar mechanisms occur in the eye and the brain. These neuropathological processes ultimately lead to neuronal cell death and include ischaemia, inflammation, mitochondrial dysfunction (including oxidative stress), deposition of misfolded proteins, and changes in fluid dynamics [aqueous and cerebrospinal fluid (CSF)] [1, 5, 6, 9‐11].
Although common to some degree in all neurodegenerative conditions, specific events are associated more closely with certain diseases. Hence, deposition and aggregation of the misfolded proteins alpha-synuclein and beta-amyloid are believed to be key in their development in Parkinson’s disease (PD) and Alzheimer’s disease (AD), respectively [4]; mitochondrial dysfunction is particularly associated with LHON (Leber’s Hereditary optic neuropathy) and PD [12]; an important element of optic neuritis and LHON is inflammation [2, 14]; both optic neuritis and glaucoma include an ischemic aetiology [3, 8]; and finally, abnormal fluid dynamics is heavily implicated in glaucoma (through intraocular pressure) [3] and AD (CSF clearance) [7]. These overlaps are illustrated in the Venn diagram above (Fig. 1).
Fig. 1
Examples of neurodegenerative eye and brain diseases illustrating overlap of key neuropathological mechanisms
×
Anzeige
This issue of Acta Neuropathologica includes a cluster of three review papers on different aspects of neurodegeneration involving the retina, from experts in ophthalmology, neuro-ophthalmology, and neuroscience and covering glaucoma [3], Alzheimer’s disease [7], and LHON [13]. In each case, they address the neuropathological mechanisms that highlight why the retina may serve as a valuable model to study brain disease. They include molecular advances, evidence for commonalities between brain and eye changes, cell death processes, and recent updates on targets for therapy. Furthermore, they promote the idea that due to its accessibility, the eye can be a tool through which disease activity and treatment response can be assessed with widespread applications for neurological disease. This cluster will hopefully be of interest to neuropathologists, ophthalmic pathologists, neuroscientists, and neurologists intrigued by how and why it might be possible to eye the brain.
Acknowledgments
The author acknowledges the Wellcome Trust for supporting research in the group for providing the funds.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.
Mit e.Med Neurologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes, den Premium-Inhalten der neurologischen Fachzeitschriften, inklusive einer gedruckten Neurologie-Zeitschrift Ihrer Wahl.
Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.
Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.
Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.
Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.
Update Neurologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
